2022 AWARD RECIPIENTS
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Award</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovative Research Awards</td>
<td>2</td>
</tr>
<tr>
<td>Innovative Research Award for Community Practitioners</td>
<td>14</td>
</tr>
<tr>
<td>Career Development Research Awards</td>
<td>16</td>
</tr>
<tr>
<td>Investigator Awards</td>
<td>30</td>
</tr>
<tr>
<td>Scientist Development Awards</td>
<td>36</td>
</tr>
<tr>
<td>Tobé and Stephen E. Malawista, MD Endowment in Academic Rheumatology</td>
<td>48</td>
</tr>
<tr>
<td>Education and Training Awards</td>
<td>50</td>
</tr>
<tr>
<td>Preceptorships</td>
<td>58</td>
</tr>
<tr>
<td>ACR Convergence Awards</td>
<td>67</td>
</tr>
</tbody>
</table>
The Innovative Research Award encourages independent investigators to conduct novel studies that generate new insights into the cause, progression, treatment, and outcomes of rheumatic diseases.
The role of T cells in RA is established, but nearly all research has focused on CD4 T cells. We show that CD8 T cells are highly expanded in inflamed RA synovium. These CD8 T cells are not the typical granzyme (Gzm) B+ CTL. Instead, they express high levels of GzmK. Remarkably, we find that GzmK activates complement. We show that GzmK can cleave C4 to C4b and C2 to C2a with formation of an active C3 convertase (C4b+C2a), which can cleave C3 to C3a and C3b. We show that fibroblasts express the highest amounts of complement components in the synovium. Just-published research (Immunity 54, 1-20, 2021) shows that complement activation drives synovial fibroblast priming with mTOR activation including downstream metabolic changes and inflammation.

We propose to determine if CD8 T cell-derived GzmK can induce synovial fibroblast activation and metabolic changes by mediating local cellular complement activation either extracellularly or intracellularly, via the recently identified composome. In Aim 1, we ask if the complement components produced by synovial fibroblasts are targets for GzmK-mediated complement activation. We define how the expression, localization, and secretion of complement change after stimulation of synovial fibroblasts with IFN or TNF. Then, we will determine where GzmK elicits formation of an active C3 convertase—whether in the extracellular space, in intracellular compartments, or both. In Aim 2, we define the ability of GzmK to induce inflammatory priming of synovial fibroblasts via complement activation by determining the effects of recombinant or CD8 T cell-derived GzmK stimulation on the inflammatory and metabolic state of synovial fibroblasts and if these effects are mediated by complement.

Together, these studies will define a new CD8 T cell—GzmK—complement activation pathway that can drive inflammatory activation of fibroblasts and other cells that are highly relevant to understanding the tissue pathology in RA and point to GzmK as a new therapeutic target.
Systemic lupus erythematosus (SLE) is driven by adaptive-immune cells via autoantibody production and innate-immune myeloid cells via impaired autophagy and chronic inflammation induced by Toll-like-receptor (TLR) and ITAM signaling. Myeloid dendritic cells (DCs) drive SLE in humans and in mouse models. In patients, kidney and other organ damage can be slowed via immunosuppression, which increases susceptibility to infection. Defining mechanisms by which DCs integrate proinflammatory and suppressive signaling inputs to support healthy immunity or to drive immune dysregulation remains an obstacle to developing better-targeted therapies for SLE. Functional loss of the Src-family kinase Lyn is a risk factor for human SLE and a driver of DC dysregulation. Lyn is expressed as two splice variants (LynA and LynB), which have been treated almost uniformly in the literature as a single entity. We recently generated isoform-specific LynA knockout (KO) and LynBKO mice and found that loss of LynB is the dominant trigger of lupus and increased TLR4 signaling in DCs and blood leukocytes.

We hypothesize that LynB protects against lupus-like disease by interacting with negative-regulatory signaling machinery in DCs, suppressing TLR signaling, promoting autophagy, and dampening inflammatory cytokine production. With the long-term goal of identifying new, safer therapies to block the progression of SLE, we propose to study LynB in cells and in vivo by (1) Defining the roles of LynA and LynB in DC TLR and autophagy pathways; (2) Defining the interactomes and substrates of LynA and LynB in DCs; and (3) Assessing contributions of DCs and B cells to LynBKO-driven lupus. Our novel LynAKO and LynBKO mice open the door to elucidating mechanisms directing activating vs. inhibitory functions of Lyn.

Ultimately, our insights into lupus pathogenesis and immune regulation will inspire the development of precision therapies and lead to safer, more effective treatment options for SLE patients.
The spondyloarthritis (SpA) spectrum diseases share the feature of pathologic enthesial bone formation. This results in significant pain, inhibited mobility, and disability for patients. Although the BMP and Wnt signaling bone anabolic pathways have been implicated in the pathogenesis of enthesial bone formation, and mechanical stress contributes, the exact mechanisms by which bone is formed remain unclear.

Our preliminary data indicate that recognition of DNA, a Cell Death-Associated Molecular Pattern (CDAMP), by enthesial macrophages, and subsequent activation of the cGAS/STING pathway, may play a critical role. We show that in a mouse in which the enzyme DNase II is deleted leading to accrual of DNA in macrophages, there is evidence of significant new bone formation that is dependent upon an intact STING pathway. We will test the hypothesis that DNA from apoptotic or dying cells is engulfed by macrophages, leading in a cGAS/STING-dependent manner to the local production of anabolic factors that promote enthesial bone formation. Studies in this grant will determine the role of mechanical stress in the process of enthesial bone formation, using two relevant animal models. We will use AAV vectors to deliver DNase locally and quantify changes in enthesial bone formation by microCT. We will also study mice deficient in cGAS or STING to determine the contribution of this pathway to the bone formation process. Finally, we will utilize fate mapping systems available in our laboratory to determine the contribution of defined macrophage populations to enthesial bone formation and determine the transcriptional signatures regulating pro-osteogenic factors.

These studies will probe the mechanisms linking enthesal bone to inflammation and local mechanical stress and could identify a novel set of targets for the prevention or treatment of SpA-induced enthesial bone.
A Novel Interleukin-15 Receptor Antagonist for the Treatment of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease. The efficacy of current medications is limited. Interleukin-15 (IL-15) is a cytokine that is detected in serum and synovial fluid of RA patients. Administration of IL-15 leads to the development of severe inflammatory arthritis in mice. Thus, IL-15 signaling is a potential target for treatment of RA.

We have discovered a new peptoid compound (IFRA3, Interleukin-15 receptor antagonist 3) that directly binds to and inhibits the IL-15 receptor. As a result of IL-15 inhibition, IFRA3Q1 (a tetramer of IFRA3) suppressed CTLL-2 cell proliferation (which depends on IL-15 activity) and exhibited strong in vivo anti-inflammatory activity in carrageenan-induced inflammation in mice. Furthermore, IFRA3Q1 inhibited collagen-induced arthritis in mice. The long-term goal of this study is to develop a new and effective RA therapy. The Specific Aims are to (1) Determine the therapeutic efficacy of IFRA3Q1 in murine models of human RA; and (2) Optimize the anti-inflammatory efficacy of IFRA3Q1 for arthritic therapy using medicinal chemistry. The efficacy of these compounds in arthritis suppression will be evaluated in vitro as well as in vivo in mice. IFRA3 has superior pharmaceutical qualities such as stability, cell/tissue permeability, and non-immunogenicity. We plan to understand the molecular action of IFRA3 and to further validate this new therapeutic paradigm. We expect to observe significant anti-arthritis activity with IFRA3Q1 and its optimized derivatives. The specificity and downstream mechanism of IFRA3Q1’s action will be defined. Optimized IFRA3Q1 derivatives are likely to show improved activity in suppressing inflammation and arthritis.

These preclinical studies will lay the groundwork for future translational studies in RA.
Despite proven benefits and widespread endorsement of a treat-to-target (TTT) strategy in RA, implementation in the U.S. is low, as patient reluctance to initiate or escalate care remains a significant barrier to TTT adherence. Improving clinical outcomes requires developing interventions designed specifically to improve patient decision-making and buy-in to TTT strategies. To effectively communicate the benefits associated with TTT, interventions must reflect in-depth understanding of the complex influences on patient decision-making, such as culture, family, peers, media, and social group, as well as cognitive and emotional factors.

In a prior study, we used the Mental Models Approach to Risk Communication to identify critical discrepancies between the rheumatologist and patient mental models for RA treatment. Many patients who have struggled to initiate or escalate DMARDs emphasized the importance of learning from their peers, in addition to receiving information from their rheumatologists, prior to making a treatment decision. To address this need, we developed tailored patient narratives in the form of videos in which patients with RA described their experiences making difficult treatment decisions, designed to support patients who are hesitant to initiate or escalate DMARDs. We aim to determine how best to incorporate patient narratives into clinical practice by conducting semi-structured interviews with key stakeholders (patients, clinicians, nurses, and office staff), as well as performing usability testing. We will then conduct a pretest-posttest study to evaluate feasibility and clinical outcomes six months prior to and six months after, introducing the tailored videos.

The data generated from this study regarding enrollment, implementation of the intervention, and the potential effect of the videos on decisional conflict, choice predisposition, shared decision-making, and TTT rates will determine whether proceeding with a more rigorous trial is justified.
Much of the evidence demonstrating the impact of SLE on patients' lives, functioning, and quality of life has been generated from observational research, e.g., epidemiologic or cohort studies. For this type of research, in-person clinical assessments are often not feasible. Two primary aspects of disease status are relevant in SLE: disease activity and accumulated disease damage.

A validated patient-reported proxy of physician-assessed disease damage has been developed by our group. However, the only existing patient-reported measure of SLE disease activity has no correlation with the physician-assessed disease activity. The proposed project will address the need for a validated, patient-reported measure of SLE disease activity that can serve as a proxy for physician assessment. Project Aims are to (1) Develop the patient-reported SLE Disease Activity Questionnaire (SLEDAQ); and (2) Conduct cross-sectional and longitudinal validation studies of the SLEDAQ in two leading SLE clinical settings. An exploratory Aim will conduct a preliminary examination of the feasibility and usefulness of SLEDAQ in telehealth encounters. The study team for this project is uniquely qualified to perform the work, having successfully developed, tested, and validated the patient-reported proxy of SLE disease damage mentioned above.

Successful completion of this project will provide researchers with a questionnaire that can feasibly be integrated into observational research, and thereby increase the validity and scientific rigor of research into important issues surrounding the impact of SLE, quality of care, disparities in health care access and quality, and patient outcomes. The measure may also have clinical usefulness in tracking disease activity, as most clinical practices cannot or do not conduct formal assessments of activity, and in telehealth settings.
Among patients with rheumatoid arthritis (RA), pain may persist even when inflammation is controlled. This pain may be due to pain centralization, a process that changes the way the brain and spinal cord regulate pain.

The goal of this proposal is to develop insights into the processes underlying pain centralization by studying the relationship between gene expression in monocytes (a type of white blood cell) and pain centralization. The rationale for studying monocytes is based on rodent models showing that monocytes are involved in maintaining chronic pain. The hypothesis is that uniquely characteristic patterns of gene expression are associated with pain centralization. The Specific Aims are to (1) Identify gene expression signatures in monocytes associated with pain centralization; and (2) Establish if the gene expression profiles predict pain after treatment with disease-modifying antirheumatic drugs (DMARDs). Fifty subjects with RA will be assessed before and 12 weeks after starting a DMARD. Subjects will complete surveys to characterize their pain experience and undergo quantitative sensory testing (QST) to assess patterns of pain sensitivity associated with specific pain pathways. Blood will be drawn to collect monocytes for RNA-sequencing. Machine-learning techniques will be used to model if gene expression is (a) Associated with QST patterns of pain centralization; and (b) Predictive of pain response after DMARD therapy. This research is innovative because it uses (1) Cutting-edge functional genomic approaches to identify pathways associated with chronic pain in RA; and (2) QST, in addition to self-reported measures of pain, to assess pain centralization.

This research is impactful because it would enable the development of non-opioid analgesics for chronic pain in patients with RA. This proposal is in-line with the Foundation’s goal to support research that studies biological parameters associated with clinical manifestations and responses to therapy.
Radiofrequency Ablation for Chronic Knee Pain After Total Knee Arthroplasty (RACK TKA)

Each year over 600,000 adults undergo TKA in the United States. While TKA successfully improves function and pain in most patients who undergo the procedure, up to 40% subsequently report chronic pain, despite a well-functioning prosthesis. Chronic pain after TKA reduces quality of life and function, and increases risk of depression, anxiety, and long-term opioid use. However, patients with chronic pain after TKA are in a double bind because of a paucity of specific treatment options and lack of knowledge among health care providers about post-TKA knee pain. Orthopedists may view the TKA as a technical “success,” while non-surgical practitioners may have trepidation intervening on a prosthetic knee following TKA. Genicular nerve radiofrequency ablation, which effectively reduces chronic pain and improves physical function among people with knee osteoarthritis, is a potential treatment for chronic pain after TKA. It uses a high-frequency electrical current to selectively denervate nociceptive input from the periphery to the central nervous system without damaging motor fibers. Preliminary evidence from observational case reports and a small clinical trial describe the initial efficacy of radiofrequency ablation in reducing chronic pain after TKA. Even though it is being used clinically, clinical trials with robust methodologies comparing an active and sham treatment are needed to estimate the acceptability, safety, and efficacy of radiofrequency ablation in people with chronic pain after TKA in the U.S.

The overall objective of this six-month study is to evaluate radiofrequency ablation as a clinically useful treatment. We will accomplish this with a double-blinded sham-controlled randomized clinical trial evaluating acceptability, safety, and potential for efficacy of genicular nerve radiofrequency ablation among 30 people=one year post-TKA who report an unacceptable symptom state and chronic pain.

Our long-term goal is to evaluate radiofrequency ablation as a readily available, non-surgical, non-opioid treatment to reduce chronic pain in people after TKA performed for knee osteoarthritis.
The majority of patients with psoriatic arthritis (PsA) continue to have active symptoms on therapy.

We hypothesize that addressing “off-target” symptoms, comorbidities, and lifestyle factors through a holistic management approach will improve disease impact and increase the probability of achieving minimal disease activity (MDA). The Aim of this study is to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with PsA. We will conduct a single-arm trial that employs a telemedicine-based intervention conducted by nurses and nurse practitioners. Visits will be structured based on the previously validated PsoWell model, a motivational interviewing technique, and will employ a set of PDF and/or digital tools to assist patients in setting goals and achieving lifestyle changes (i.e., sleep hygiene to improve fatigue and sleep). In the proposed study, patients with PsA who are stable on therapy but have active symptoms as measured by the PsA Impact of Disease (PsAID) questionnaire will be enrolled. Two telemedicine visits will be conducted between standard office visits. Patients will select a target symptom and/or comorbidity, set goals, and follow up with the provider. Outcomes of the study include feasibility, acceptability to patients and providers, and effectiveness (achievement of PSAID score<4, the patient acceptable symptom state, and MDA).

At completion of the proposed study, we will have data to support use of the PsoWell model via telemedicine in clinical practice and the information needed to plan and conduct a pragmatic trial to address a holistic management strategy compared to standard of care in patients with PsA.

* These funds are available in partnership with AbbVie and UCB, with additional support provided by Bristol Myers Squibb.
The goal of this project is to investigate interbacterial and host-bacterial molecular interactions associated with relapse in granulomatosis with polyangiitis (GPA). GPA is a systemic vasculitis associated with destructive sinonasal inflammation and frequent relapses. It is unknown what incites disease activity in GPA. Mechanistic and epidemiologic studies suggest microbes, in particular nasal microbiota, may be an important contributor to relapse in GPA. While previous studies in GPA focused on a single pathogenic microbe in isolation, studies in other populations demonstrate that interspecies interactions, either synergistic or antagonistic, influence pathogenicity. In GPA, little is known about polymicrobial interactions in the nasal cavity and their effects on immune responses.

Work from our group has uncovered novel relationships between nasal bacteria in GPA. Using unbiased molecular sequencing of nasal swabs obtained from a longitudinal cohort of patients with GPA, we identified dynamic changes months prior to the onset of clinical relapse in nasal Staphylococcus and Corynebacterium. Our findings are consistent with prior studies which demonstrated direct interactions between Staphylococcus aureus and Corynebacterium species in vitro. Building from our sequencing-based epidemiological studies, we will perform culture-based investigations to define the molecular mechanisms that govern these correlations.

We plan to investigate how bacteria interact with each other and how bacteria interact with the host. Leveraging a well-characterized biorepository of over 500 nasal swabs from 106 GPA patients to harvest bacterial strains and epithelial cells, we will: (1) determine the bacteria-bacteria molecular interactions and strain heterogeneity of nasal bacteria in GPA, and (2) investigate host-bacteria interactions in vitro using cultured human nasal epithelial cells from patients with GPA. The outcome of this study is a better understanding of the mechanisms by which communities of nasal bacterial incite relapse in GPA. This is the first step towards developing antimicrobial strategies that target disease-causing pathways while preserving the overall “healthy” diversity of the microbiome. Ultimately, we will broadly expand our knowledge of the role of the respiratory tract microbiome in autoimmunity.
Forty-nine years after the recognition that HLA B27 predisposes to spondyloarthritis, the mechanism of this effect remains elusive. We hypothesize that HLA B27 shapes the immune response to commensal bacteria. This results in a dysbiosis.

This hypothesis will be tested in healthy individuals who are HLA B27 positive, healthy individuals who are HLA B27 negative including a group which is HLA B7 positive, subjects who are HLA B27 positive or HLA B27 negative with axial spondyloarthritis, and subjects with Crohn’s Disease.

The immune response to commensal bacteria will be measured as the IgA response in the intestine or feces and the IgA and IgG response in serum. These studies will clarify the mechanism by which HLA B27 predisposes to disease. This enhanced understanding has potential implications for every immune-mediated disease that has an HLA association. It should lead to improved therapy or prevention that deals with the root cause of spondylitis.

* Funding for this award was provided by The Prestidigitator Fund, making good happen.

** This funding opportunity is possible through the Donor Direct program, allowing supporters to financially support awards within a narrowly focused area.
Rheumatoid arthritis (RA) affects approximately 1% of our population, or 2.5 million Americans. RA is a chronic, disabling autoimmune disease in which the body attacks its tissues. If patients with RA do not receive treatment, this aggressive disease will severely destroy the joints to the point where they can no longer function. RA is also associated with depression, cardiovascular disease, and psychosocial stress. As RA progresses, performing simple daily activities becomes more challenging for patients suffering from the disease. There is no cure for RA and up to 50% of RA patients do not respond to the current therapies; therefore, novel therapeutic strategies are urgently needed.

The goal of this project is to develop a safe therapeutic agent for patients who do not respond to current therapies. As such, we have identified a novel pathway that can markedly alleviate inflammation and bone erosion in RA cells by rebalancing the pro-repair over the pro-inflammatory networks. This mechanism of action is not limited to a specific inflammatory factor and its function will impact multiple immune cell types that are in crosstalk. We are proposing a unique way of combating RA joint inflammation and bone erosion which has not been tested previously. Our short-term goal is to evaluate the effectiveness of blocking the identified network to rebalance pro-repair over pro-inflammatory factors. Our long-term goal is to engineer a specific inhibitor that can target metabolic malfunction by switching the inflammatory phenotype to a pro-repair immune response in the RA joints.

We hope that our work will lead to a novel type of treatment that can be a suitable option for suffering RA patients who are nonresponsive to traditional therapies.
The Foundation recognizes the unique potential for research performed by rheumatologists and rheumatology professionals in community-based environments to advance our understanding of rheumatic diseases, their treatment and how to improve patient outcomes.

This award is targeted to community practitioners, who, in addition to being engaged in patient care or conduct, are interested in conducting research.
Use of telemedicine has exponentially increased in adult and pediatric rheumatology during the COVID-19 pandemic. Although for patients with inflammatory arthritis a comprehensive hands-on joint exam is crucial for an accurate assessment of disease activity and medical decision-making, such an exam is not assessed during telemedicine visits. We are acutely aware that methods of examination via telemedicine need improvement, validation, and standardization.

A recent survey amongst pediatric rheumatologists indicated that the use of the pediatric Gait, Arms and Legs (pGALS), a simplified musculoskeletal examination that assesses joint range of motion, was the most widely used visual exam during telemedicine visits at the height of the pandemic. It has since been proposed that this variation of the pGALS, known as the video-pGALS (v-pGALS), is one systematic exam approach that can be used in conjunction with patient history and patient-reported exam during telemedicine visits. However, there are no studies that compare its performance to the in-person joint examination. Additionally, infrared thermal imaging has been evaluated as a screening or supplementary tool for detecting or following up active arthritis in animal models, osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis (JIA). Infrared thermal imaging is a quick and noninvasive tool that has been proven sensitive in identifying active arthritis in knees. Thus, we believe that infrared technology has the potential to improve remote assessment of joint inflammation.

This study aims to assess the clinical performance of a joint count questionnaire with and without video-exam inspection during telemedicine compared to an in-person physician conducted joint exam in adults and children with chronic inflammatory arthritis. We also plan to further develop and validate the within-limb calibrated temperature measurement of joints using previously-established algorithms with a smartphone-attached thermal camera. Lastly, we will determine the added value of thermal imaging for physicians to assess joint disease status in a telemedicine setting and the utility of thermal imaging during long-term care.

* These funds are available in partnership with AbbVie and UCB, with additional support provided by Bristol Myers Squibb.
Increasing concerns over the decline in federal funding for rheumatology research have forced many investigators to reconsider their careers, resulting in fewer researchers making the important discoveries necessary to advance treatments and find cures.

The Career Development Research Awards are designed to encourage early and midcareer investigators to continue vital research into the cause, prevention, and treatment of rheumatic diseases.
Career Development Bridge Funding Award: R Bridge

The R Bridge Award encourages essential rheumatology research by supporting promising investigators who are revising outstanding NIH R01 or VA RCS/ORD award applications.
Role of the CD47 Pathway in Rheumatoid Arthritis Pathogenesis and Treatment

CD47 is a ubiquitously expressed surface protein which both regulates phagocytosis by interacting with SIRP-a to initiate “don’t eat me” signaling, and modulates fibroblast matrix turnover and bone homeostasis via its interaction with thrombospondin-1, is elevated in RA, and may play multiple roles in disease.

The application’s central hypothesis is that CD47 is critical to RA pathogenesis and reduction of CD47 signaling will ameliorate or reverse inflammatory arthritis via effects in both immune and mesenchymal cells. Furthermore, we hypothesize that over-expression of CD47 in RA prevents clearance of pathogenic immune cells from the synovium, promotes fibroblast activation, and accelerates bone loss. We will first test this hypothesis by characterizing CD47 and its binding partners in RA synovium histologically, functionally in relevant cells, and by single-cell RNA sequencing. Next, we will explore the role of CD47 in vivo by assessing clinical, histologic, radiographic, and genomic alterations induced by CD47 deficiency in mouse models of RA. Finally, we will test anti-CD47 based therapeutic strategies in synovial organoid cultures and in vivo arthritis models.

This application will support Dr. Korman’s effort to generate preliminary data to improve and resubmit an R01 application investigating the role of CD47 in rheumatoid arthritis (RA) and career development.
Advanced Vessel Wall MR Imaging of Scalp and Orbital Arteries in Patients with Giant Cell Arteritis

GCA is a relapsing systemic vasculitis which frequently involves the scalp and orbital arteries. About 20% of patients present with visual impairment which can rapidly progress to blindness (“ocular GCA”). There is a critical need for a noninvasive imaging test that can accurately diagnose GCA, identify the subgroup with ocular GCA, and longitudinally monitor treatment response and relapse. cVW-MRI has the potential to address this need by visualizing vascular inflammation of multiple scalp and orbital arteries.

The goal of the project is to determine the utility of cranial vessel wall magnetic resonance imaging (cVW-MRI) in the diagnosis and disease surveillance of patients with giant cell arteritis (GCA, formerly “temporal arteritis”). This prospective observational study will enroll patients with suspected GCA, enriching for ocular involvement. Aim 1 will determine the utility of cVW-MRI as a noninvasive diagnostic tool in GCA by comparing scalp and orbital vessel wall enhancement in patients with suspected GCA, including ocular GCA. Aim 2 will define the longitudinal changes in cVW-MRI associated with disease activity and outcomes, including irrecoverable vision loss.

The outcome of this work is an imaging test that detects vascular inflammation of both the scalp and orbital arteries in GCA. The direct impact on patient care is the implementation of a single, 35-minute imaging exam that enhances current approaches to diagnosis and monitoring of disease activity in GCA. The RRF R Bridge Award will provide the critical support needed to transform clinical practice paradigms in GCA.
Career Development Bridge Funding Award: K Supplement

The K Supplement Award encourages junior investigators to expand promising research by providing additional support to cover research costs and help investigators become independent.
Disease and Glucocorticoid-related Cardiovascular Toxicity in Childhood Lupus

Adverse effects of glucocorticoid use and premature cardiovascular disease are major sources of morbidity and mortality in persons living with childhood-onset lupus and other rheumatic conditions. In order to compare the effects of different immunomodulatory treatment regimens on cardiovascular health in children with pediatric-onset systemic lupus erythematosus (pSLE), we need standardized, pediatric-specific tools to quantify both cardiometabolic glucocorticoid toxicity and persistent cardiovascular inflammation. Neither glucocorticoid dosing targets nor cardiovascular disease biomarkers developed in adults are readily extrapolated to the pediatric population, in which dosing is weight-based, and overt atherosclerotic plaque is rarely detected. Recent advances include the development of a new pediatric glucocorticoid toxicity index (GTI), which may be a better tool for quantifying glucocorticoid exposure compared to dose or duration, but has yet to be validated in children with pSLE. Therefore, the objectives of this study are to quantify glucocorticoid doses associated with varying levels of toxicity assessed using the pediatric GTI and subsequent risk of subclinical atherosclerosis in pSLE, and to identify plasma biomarkers of subclinical atherosclerosis in a well-characterized pSLE cohort already undergoing comprehensive CV testing. We will calculate pediatric GTI scores by linking medical records to Lupus Registries at Boston Children's Hospital and the Children's Hospital of Philadelphia and evaluate time-varying associations between dose, duration and toxicity, as well as measures of endothelial dysfunction and carotid intima-media thickness among a subset of subjects enrolled in longitudinal cardiovascular testing. We will then perform targeted proteomic analysis of samples collected at the time of cardiovascular testing. Responsive glucocorticoid toxicity endpoints and markers of persistent cardiovascular inflammation for pSLE are critical to both the design of efficacy and effectiveness studies and establishing treatment goals.
The role of Follistatin Like 1 Protein in Cardiac Inflammation and Kawasaki Disease

In this project, we are trying to understand the role of a particular protein, Follistatin Like Protein 1 (FSTL-1), in the setting of Kawasaki disease and cardiac inflammation. In an early human study, FSTL-1 is highly upregulated in Kawasaki disease and correlates with severity of disease. In subsequent murine data, we have found that knocking out FSTL-1 results in decreased inflammatory infiltrate in the heart, and that the immediate acute serum concentrations of FSTL-1 correlate with severity of disease, two findings which on the surface seem to perhaps be in contradiction to each other, but may indicate that FSTL-1 plays an immunoregulatory role in cardiac inflammation. In addition, administration of FSTL-1 to young mice (but not older mice) who are induced to have a Kawasaki disease model shows decrease in number of mice with disease. Despite intensive evaluation, a definitive answer as to how FSTL-1 induces this regulatory function is not clear. To try to answer this question, we have managed to develop a technique to create a single cell suspension of cardiac tissue with high viability of cells, and propose to use single cell RNA seq to understand, with high resolution, the difference in DNA expression between an FSTL-1 knockout and intact mouse during the Kawasaki disease model and treatment.
By inhibiting immune checkpoints including cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) and enhancing antitumor immunity, immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment; however, ICIs are associated with life- or organ-threatening complications, termed immune-related adverse events (irAEs), including inflammatory arthritis (arthritis-irAE). To avoid abrogation of the antitumor immunity, mechanism-rooted immunomodulation is critical in managing irAEs; however, mechanisms of irAEs are elusive. Analyzing synovial fluid and blood samples of arthritis-irAE patients, we discovered enhance Th17 cell signatures and steroid resistance in arthritis-irAE induced by combined CTLA-4 and PD-1 inhibitor therapy (PMID: 35413951). In parallel, we developed arthritis-irAE murine models recapitulating patients' clinical settings. Notably, we also found that blockade of Th17-related cytokines, interleukin-6 and tumor necrosis factor alpha, might be a new way to treat arthritis-irAE without abrogating antitumor immunity. Based on our preliminary data, we hypothesize that targeting of Th17-associated factors is a promising strategy for arthritis-irAE therapy while maintaining antitumor immunity. To address our hypothesis, we will Aim 1) Determine the cellular and molecular mechanism(s) underlying arthritis-irAE in vivo; and Aim 2) Develop the optimal therapeutic strategies for arthritis-irAE with preservation of antitumor immunity in vivo. Successful completion of the project will help us to understand mechanisms as well as to develop ideal therapeutic strategies for arthritis-irAE, a rapidly emerging clinical entity in rheumatology.
Skeletal myopathy in systemic sclerosis or scleroderma (SSc) is poorly understood despite its association with increased disability and mortality. We have previously published that the spectrum of muscle histopathology ranges from inflammatory to a fibrosing myopathy. In particular, a subset of patients with a fibrosing myopathy have poor outcomes including cardiac death. Therefore, in order to tackle the heterogeneity of muscle disease in SSc, my K23 project has focused on the development of a Myopathy sub-cohort in the Hopkins Scleroderma Registry in order to develop a classification schema predictive of outcomes. A unique feature of the cohort is a protocolized treatment algorithm has been instituted in those with a myopathy. Patients also obtain advanced, quantitative muscle MRI including diffusion weighted imaging and T2 mapping to capture early evidence of muscle disease and recognize patterns of muscle involvement.

The current proposal expands the current K23 award by assessing treatment response with advanced, quantitative muscle MRIs in SSc associated myopathy. Our preliminary data revealed that there is a predilection of obturator externus muscle involvement in SSc myopathy when compared to normal controls, thereby highlighting that MRI is a sensitive and effective tool in detecting early muscle disease. We hypothesize that quantitative MRI will be able to assess treatment response better than clinical measures of muscle disease activity. To test this hypothesis, we will implement post-treatment muscle MRIs in a subset of patients including disease controls and compare the quantitative changes seen on MRI with creatine kinase and muscle strength. The overall goal of this proposal is to determine whether quantitative muscle MRI can be used as an imaging biomarker in the assessment of muscle disease activity after treatment. The results of these findings will lay the foundation to pursue an R01 focused on outcome measurement in SSc associated myopathy.
Career Development Bridge Funding Award: K Bridge

The K Bridge Award encourages junior investigators to continue conducting research into novel ideas while reapplying for an NIH or VA career development award.
Kidney disease in lupus is a major cause of kidney failure and death. Current therapies are toxic and often ineffective so there is an urgent need to discover and validate new targets. Our studies of 155 patients (with AMP-SLE) and common mouse models with lupus kidney disease identified comparable intrarenal macrophage states that differentiated from similar infiltrating monocyte precursors and that were associated with kidney damage. We hypothesize that injury-associated macrophages differentiate in response to lupus-associated kidney injury, and localize to tissue regions to regulate local homeostasis and immunity through conserved functions. Our goal is to determine the biological role and regulators of these injury-associated macrophages using human samples and leveraging lupus mouse models that we have characterized. This award will enable the collection of additional data to support 3 complementary aims for K08 submission.

Aim 1 will identify the kidney lesions and cell types that may promote the differentiation of infiltrating monocytes to injury-associated states in humans. This aim will also examine if the extent of differentiation is linked to kidney function or outcomes. Aim 2 will determine the role of 15 conserved transcription factors regulated over monocyte differentiation to injury-associated states. We will examine their role in repair, immune function, and differentiation in vitro. Aim 3 will examine the role of these conserved transcription factors in the native injured kidney from a lupus mouse model. Here, we will measure gene programs and states regulated by each transcription factor in kidney macrophages to identify their role in a physiologic context. This proposal offers a powerful approach that would provide the basis for a new histological classification based on the immune response, identify monocyte mechanisms that modify disease as potential targets, and set the stage for future mechanistic studies.
Juvenile Idiopathic Arthritis (JIA), the most common chronic rheumatic disease in childhood, can result in irreversible joint damage and long-term functional disabilities if inadequately treated. Accurate determination of disease activity for each child is critical to avoid both overtreatment but also undertreatment of JIA. Diagnosis of arthritis in children is based on the presence of joint swelling and limited range of motion and/or tenderness on palpation. Given the young age of children at diagnosis, the report of joint pain or limitation of motion might be limited. In addition, clinical assessment of active arthritis in children is challenging.

Musculoskeletal ultrasound (MSUS), a non-invasive diagnostic modality, offers an objective evaluation of the joint. MSUS may detected moderate to severe synovitis in 30% of joints determined as normal by AJC, suggesting that MSUS may improve the assessment of joint involvement in JIA. However, there is a knowledge gap on the clinical significance of MSUS findings in children.

The central hypothesis of our study is that a 10-joint MSUS examination and score (MSUS-10 score) correlates with JIA disease activity and response to therapy. This hypothesis will be tested with three specific aims:

Aim 1. Determine the convergent validity of the MSUS-10 score for the assessment of JIA disease activity.
Aim 2. Evaluate the sensitivity to change of the MSUS-10 score at 6 months
Aim 3. Explore the relationship of the MSUS-10 score with biologic markers of inflammation.

The global objective of this project is to understand if the MSUS-10 examination and score may support the decision-making process which in turn will improve the outcomes of children with JIA. We hypothesize that the MSUS-10 has a moderate to strong association with clinical and laboratory markers of JIA disease activity and that MSUS-10 score exhibits good outcome metrics for the assessment and quantification of MSUS inflammatory burden in JIA.
Rheumatoid arthritis (RA) is common, affecting approximately 1% of the world population. Delay in effective treatment results in increased morbidity and mortality, and a heavy economic burden. Current treatment strategies are empiric because we have no markers to suggest which therapy is best for an individual. Tumor necrosis factor inhibitors (TNFi) are the most common initial biologic treatment employed. Responses are variable, with approximately 30% not responding and another 30% having only partial response.

We have shown in test and validation cohorts that pre-treatment circulating type I IFN (T1IFN) activity predicts non-response to TNFi. Pre-treatment IFN-β to IFN-a activity ratio>1.3 was strongly predictive of non-response to TNFi. No patient with a ratio>1.3 achieved remission or low disease activity. In RA, monocytes (Mo) from the blood invade synovium, and local stimuli drive expansion of macrophage (Mf) populations. We used single-cell analysis to study blood Mo gene expression in RA patients with high vs. low IFN-β-to-a activity ratio and found major differences between the groups, supporting downstream effects upon a critical effector cell population. Dr. Wampler Muskardin hypothesizes that RA TNFi non-responders have increased IFN-β relative to IFN-a, which results in increased diapedesis of Mo and associates with altered composition and pathway activation in the synovium. She will explore this overarching hypothesis by (1) Detecting differences in T1IFN, pathway activation, and histopathology in synovium of RA patients who have a EULAR good response or no response to TNFi; and (2) Determining the impact of IFN-a and IFN-β on RA Mo, Mo-derived Mf, and fibroblast-like synoviocytes. Select coursework will complement her research and fortify her skills. Results will provide fertile ground for future directions.

Dr. Wampler Muskardin will gain new skills in biased and unbiased analyses, data architecture/artificial intelligence, and in use of a bioengineered microphysiological system to interrogate human RA biology, which is needed to successfully launch and establish herself as an independent investigator advancing precision medicine in RA.
Membrane Attack Complex (MAC) and Other Complement Components as Markers of Kidney Injury and Treatment Response in Patients with Lupus Nephritis

Lupus nephritis (LN) has significant morbidity and mortality given nonspecific treatment approaches. Only 24 to 50% of patients respond to current B and/or T cell targeting treatments and 10 to 30% of LN patients progress to end-stage renal disease (ESRD) within 10 years. The complement pathway is a promising target for LN treatment because it plays a central role in pathogenesis. LN patients who respond poorly to current therapies likely have complement-mediated inflammation as the main cause of kidney damage. There is an urgent need for complement biomarkers to identify these non-responders and guide targeted therapies.

The membrane attack complex (MAC) is a viable marker of renal outcome because it causes cell membrane lysis, drives inflammation and is involved in tubulointerstitial injury. The overall goal of this proposal is to evaluate MAC and other complement components as a marker of kidney injury and treatment response. We hypothesize that LN patients with MAC and other complement components in kidney tissues and urine will have severe complement-mediated kidney injury and worse outcomes. Our hypothesis will be tested using three different approaches: immunohistochemistry, urine proteomics and single-cell RNA sequencing (scRNA-seq).

This K-Bridge award will enable me to generate preliminary data, publications and broaden the scope of this study in response to reviewers’ comments. Studies will be conducted using urine proteomics and scRNA-seq data to strengthen the premise of this research and optimize methods for a first K23 resubmission, with the following aims: 1) to associate MAC deposition in paraffin embedded kidney biopsies with renal outcomes; 2) to determine urinary complement profiles among LN patients using mass spectrometry; and 3) to identify complement gene expression in kidney cells using existing scRNA-seq data from the Accelerating Medicine Partnership (AMP) Lupus Network. We expect to find MAC in kidney tissue and urine among LN patients with worse renal outcomes and discover new complement biomarkers using omics analyses.

This study is significant because complement biomarkers can identify candidates for complement targeting therapies. The K-Bridge support will lead to a stronger K23 resubmission and prepare me for a career in omics research and biomarker discovery in lupus.
The Investigator Award encourages junior investigators to continue conducting innovative research that will be competitive for more significant funding while they establish themselves as independent investigators.
While physical activity is widely recommended as a core management strategy for persons with knee osteoarthritis, little guidance exists regarding the appropriate dose of physical activity and whether this should differ based on individual patient characteristics. Importantly, individuals with knee osteoarthritis exhibit altered gait patterns that cause repetitive, abnormal forces on the knee joint and contribute to disease progression. Thus, physical activity prescription may need to be tailored to individual gait patterns. Existing research has been limited by the use of simplified metrics and models to describe the rich data source provided by these three-dimensional, time-varying physical activity and gait pattern data, and by failing to account for both contributors to loading.

This project will characterize the role of physical activity in knee osteoarthritis progression using agnostic machine learning approaches while accounting for individual patterns of loading during walking. Deep learning will be utilized to analyze accelerometer data (as traditional summary measures or raw patterns of physical activity) along with raw patterns of ground reaction force data to examine two-year change in structural and symptomatic osteoarthritis outcomes in the Multicenter Osteoarthritis Study. We expect models including ground reaction force inputs to outperform those without ground reaction force inputs, and expect models using raw physical activity patterns as inputs to outperform those using summary physical activity measures as inputs. We will utilize saliency maps to examine whether specific patterns of physical activity are associated with worse outcomes and in an exploratory analysis, whether patient characteristics such as age, sex, and obesity are associated with these patterns.

This research will provide valuable training in deep learning and big data management for the principal investigator and will contribute to understanding appropriate patient-specific physical activity dose for knee osteoarthritis.
Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by widespread tissue fibrosis and vasculopathy. Interstitial lung disease (ILD) occurs in 50-80% of patients with SSc, and is a leading cause of morbidity and mortality. The clinical course of SSc-ILD is highly variable in expression and progression, with some patients experiencing progressive fibrosis despite receiving therapy while others remain stable without treatment. This heterogeneity results in a major unmet need for clinical tools that (1) Identify patients with SSc at highest risk for progression at baseline who would benefit from early initiation of treatment; and (2) Identify patients who may not be responding to their current ILD treatment and in whom alternative treatments should be considered.

In this proposal, we will leverage extensive imaging data (>4,500 high resolution computed tomography scans (HRCT)) and longitudinal outcomes from a large cohort of patients with SSc (n>1,300) seen at Mayo Clinic to develop radiomic biomarkers that associate with ILD progression. These radiomic biomarkers will be developed utilizing quantitative CT (QCT) technology combined with advanced statistical analytic approaches. We aim to (1) Identify radiomic biomarkers that associate with ILD progression in SSc patients on baseline HRCT; and (2) Establish the short-term rate of change in parenchymal features on QCT that associate with long-term ILD progression.

These studies will lay the foundation for future work aimed at validating these ILD radiomic biomarkers for widespread clinical and investigative trial use.
The Impact of Axial Spondyloarthritis Treatment on Chronic Opioid Use

Inflammatory back pain is the predominant feature of axial spondyloarthritis (axSpA), which affects over 1% of U.S. adults. Despite the rise in biologic use in axial spondyloarthritis (axSpA), many still do not experience a meaningful improvement in back pain symptoms. Up to one quarter of individuals with axSpA have been prescribed chronic opioids.

This proposal will evaluate how the timing and sequence of currently recommended therapies (tumor necrosis factor inhibitors and physical activity) impact chronic opioid use. Using advanced epidemiologic methods, we will leverage multiple complementary data sources, specifically aiming to (1) Describe time trends in opioid prescriptions in relation to the approval of TNFi for axSpa using three separate cohorts of individuals with ankylosing spondylitis (AS) from three real-world data sources. We will calculate the annual percent change of opioid prescription pre- and post- TNFi approval for AS. We hypothesize that opioid prescriptions decreased after TNFi approval; and (2) Assess the relation of early TNFi initiation to risk of chronic opioid use in a cohort of ~4000 individuals with AS starting TNFi therapy from the VA national administrative database between 2003 and 2019. We will examine the association of early TNFi initiation (within six months of diagnosis) with incident chronic opioid use. We hypothesize that early TNFi initiation results in a lower odds of chronic opioid use compared to delayed initiation; and (3) Assess the relation of physical activity to risk of chronic opioid use in a prospective cohort of ~1000 AS patients with data on medication use, physical activity, and disease activity measures. We hypothesize that greater physical activity is associated with later reduction in chronic opioid use in AS.

The findings from this proposal are expected to inform future guidelines on therapy in axSpA and impact clinical prescriptions of opioids and other axSpA therapies.
Systemic lupus erythematosus (SLE) affects ~250,000 Americans. Vaccine-preventable infections are a leading cause of death for patients with SLE, underscoring the importance of vaccines in the care of SLE patients. SLE patients are highly vulnerable to critical illness from COVID-19, and the ACR recommends that SLE patients be vaccinated against COVID-19. It remains unclear whether the mRNA COVID-19 vaccines are immunogenic in SLE patients, many of whom are immunosuppressed. Similarly, it remains unclear whether mRNA COVID-19 vaccines will increase autoantibody production in SLE, a condition characterized by antibodies to nuclear antigens and in which RNA is known to stimulate unregulated inflammation.

To answer these questions, we analyze biobanked sera from SLE patients who received a COVID-19 mRNA vaccine to (1) Determine the humoral immunogenicity of the vaccine in SLE patients who are on various immunosuppressant medications; (2) Determine whether COVID-19 vaccination is associated with increased dsDNA, increased ESR, increased antiphospholipid antibodies, or lupus flare; and (3) Determine whether COVID-19 mRNA vaccination leads to the development of anti-spike antibodies with cross-reactivity to nuclear or cardiomyocyte autoantigens.

Collectively, these analyses will help establish the safety and efficacy of COVID-19 mRNA vaccines in SLE, which is of vital importance in an era that is likely to be characterized by expanding mRNA vaccine technology.
Systemic sclerosis (SSc) is a debilitating and potentially fatal autoimmune disease whose pathogenesis is incompletely understood. Recent research has revealed certain genetic loci that are robustly linked to SSc susceptibility.

The focus of our research is to elucidate how a validated SSc genetic risk locus, encoding Arginine to Cysteine substitution of amino acid 206 in deoxyribonuclease 1-like 3 (DNASE1L3 R206C), contributes to disease pathogenesis. Previously published work by other investigators and our own preliminary data suggest that DNASE1L3 has a key role in digesting genomic DNA within the circulation, a process that is impaired in individuals with the DNASE1L3 R206C variant. Improperly processed DNA can induce excessive activation of the immune system, but the specific DNA populations most affected in those with the DNASE1L3 R206C variant, and their downstream effects in patients with SSc, are unknown. We hypothesize that certain populations of circulating DNA are incompletely digested in SSc patients with the DNASE1L3 R206C variant, and that this DNA contributes to the observed immune perturbations in SSc.

Aim 1 of our research is designed to further define the circulating DNA profile of SSc patients with the DNASE1L3 R206C variant, examining specific populations of circulating DNA in SSc patient blood samples. Aims 2 and 3 are designed to determine downstream effects of incompletely digested DNASE1L3-substrate DNA on immune cell function, through molecular characterization of immune cells from a murine model and from SSc patients.

Together, these studies will shed light on the downstream biochemical and immunologic consequences of DNASE1L3 dysfunction, strengthening the foundation for development of targeted therapies to treat SSc.
The Scientist Development Award encourages rheumatologists and rheumatology health professionals to pursue innovative research ideas.
Understanding the Role of T cells in Rheumatologic irAEs with the Use of Deep Immune Profiling and Analytical Vaccination

The proposed research explores the mechanisms through which PD-1 checkpoint inhibition leads to rheumatologic immune-related adverse events (irAEs). In this proposal, we hypothesize that PD-1 inhibition disturbs naïve T cell quiescence in patients with rheumatologic irAEs and generates heightened effector CD4 responses that can be probed with analytical vaccination.

To explore this hypothesis, we utilize two distinct cohorts: a prospective cohort of patients with cancer that initiate PD-1 immunotherapy and are monitored for irAEs (prospective irAE cohort), and a cohort of patients with melanoma on PD-1 immunotherapy that receive annual influenza vaccination as a model analytical vaccination (melanoma/influenza vaccine cohort). Using the prospective irAE cohort, we have previously demonstrated that the naïve CD4 T cell compartment is preferentially expanded in patients with irAEs. In this proposal, we will further analyze the heterogeneity and composition of the naïve CD4 T cells to identify any subpopulations enriched in patients with irAEs. We will also interrogate the effector/memory cells generated immediately after PD-1 inhibition to understand their transcriptional profile in patients with rheumatologic irAEs. Using the melanoma/influenza vaccine cohort, we will evaluate the single-cell transcriptional profile of activated circulating T follicular helper (Tfh) and T peripheral helper (Tph) cells responding to influenza vaccination in patients with rheumatologic irAEs compared to patients without irAEs and healthy controls.

These studies will advance our understanding of the contribution of T cells in the development of rheumatologic irAEs and can be used to design targeted future therapies for these patients. They will also provide insight into the function of PD-1+ expressing cells, specifically CXCR5+ cTfh and CXCR5- Tph cells, shown to be central in the pathogenesis of primary rheumatic diseases, including RA and SLE.
Systemic lupus erythematosus (SLE) is a heterogenous, multi-organ system autoimmune disease. Dysregulation of T and B cells is characteristic of SLE. Studies suggest that autoantibodies and immune dysregulation start years before diagnosis. The etiology of SLE is unknown but likely includes genetic as well as environmental factors, such as viral infections. Increased activity of the toll-like receptor 7 (TLR7) has been suggested to play a role in the pathogenesis of SLE and dysregulation of T and B cells. Viruses are often studied in the context of active infection in patients already diagnosed with SLE and can stimulate the TLR7 pathway. Little is known about how past viral infections could predispose individuals to SLE. Murine roseolovirus (MRV) is a beta-herpesvirus that is genetically highly related to human roseoloviruses.

We have demonstrated that neonatal MRV infection induces autoimmune disease with development of autoantibodies in adult, wild-type mice. This occurs after acute viral infection has resolved, suggesting that neonatal MRV infection causes long-lasting loss of tolerance. Moreover, MRV disrupts key components of central tolerance. Adult C57BL/6 mice neonatally infected with MRV develop a lupus-like phenotype after TLR7 stimulation. Our findings suggest that roseolovirus infection results in disruption of immunologic tolerance. We propose to evaluate how MRV predisposes to development of lupus-like disease by elucidating the immunophenotype and transcriptome of T and B cells, and identifying the cells are necessary to develop disease. Furthermore, using MRV as an example, we will perform similar studies using other thymotropic viruses to investigate if disruption of central tolerance leading to autoimmunity is unique to MRV or shared amongst thymotropic viruses.

The studies performed in this proposal will provide key insight into how a virus can result in a predisposition to altered TLR7 response and SLE.
**Phosphorylation of MDA5 to Restrict Aberrant Innate Immune Signaling**

MDA5 is a conserved innate immune receptor that detects viral double-stranded RNA (dsRNA) during infection and activates the antiviral immune response. However, aberrant activation of MDA5 in the absence of infection leads to “sterile” inflammation, which is associated with increased risk of systemic lupus erythematosus (SLE) and drives lupus-like autoinflammatory diseases.

We and others have discovered that MDA5 assembles into filaments upon binding to dsRNA, which signals the production of type I interferons. However, the regulation of MDA5 filament formation is poorly understood, and the role of post-translational modifications as a regulatory mechanism remains unclear. Our preliminary data reveal that inactive MDA5 is phosphorylated at a novel site in the helicase domain, which mediates dsRNA binding. Phospho-mimetic mutation in MDA5 impairs filament formation and downstream signaling while a phosphorylation-deficient mutant enhances filamentation and constitutively activates MDA5 signaling. Here, we explore the hypothesis that phosphorylation of the MDA5 helicase domain inhibits MDA5 filament formation in the absence of viral infection, which suppresses aberrant innate immune activation in inflammatory diseases like SLE. In Aim 1, we will examine the impact of MDA5 phosphorylation on filament assembly and disassembly and determine whether phosphorylation leads to conformational changes affecting MDA5 binding to dsRNA. In Aim 2, we will assess the use of unphosphorylated MDA5 as a biomarker of MDA5 activation in peripheral blood samples from patients with SLE and develop a novel assay that detects endogenous MDA5 filament formation.

Through our precision medicine-based approach to tackling SLE, we will identify the subset of lupus patients with aberrant MDA5 activation and delineate the regulatory steps of MDA5 filament formation that can be therapeutically targeted in these patients.
Heart failure (HF) is among the most burdensome chronic diseases and a leading cause of hospitalization in the United States. Compared to the general population, patients with rheumatoid arthritis (RA) are nearly twice as likely to develop HF and are at a higher risk of HF-related mortality. Prevention of HF development and improvement of HF-related outcomes would yield substantial benefits to the longevity and quality of life in patients with RA. However, critical knowledge gaps exist in the pathophysiology and natural history of HF in RA that limit the development of effective management strategies.

The overall objective of this study is to evaluate contributions of immune, inflammatory, and fibrotic mediators of HF incidence and progression in RA beyond traditional RA disease activity measures. In Specific Aim 1, we will evaluate the contribution of RA-related immune, inflammatory, and fibrotic mediators to the development of HF, independent of traditional and established RA-related risk factors, in a prospective cohort of patients with RA. In Specific Aim 2, we will leverage a large, national cohort of RA and matched non-RA patients to determine the excess burden of HF in RA manifest through recurrent HF exacerbations, a critical feature of severe or uncontrolled HF in RA that has not been previously studied. We will additionally use national echocardiogram data to evaluate the differential burden and outcomes of HF with reduced (HFrEF) and preserved (HFpEF) ejection fraction and identify risk factors that predict more rapid ejection fraction decline in RA patients with HFrEF.

These findings will begin to elucidate the mediators of cardiac dysfunction and comprehensively characterize the burden and trajectory of HF in RA. The PI will complete an accompanying rigorous research training program that will prepare him to lead future clinical and translational studies of cardiac dysfunction in RA.
Psoriatic arthritis (PsA) is a chronic, progressive inflammatory disease of the skin and musculoskeletal system, affecting over 500,000 Americans. Despite improvement in therapies, only about half of the patients respond to therapy. In part, this is because PsA is studied and managed as if it is a single disease (polymyalgia rheumatica similar to rheumatoid arthritis). PsA, however, has high heterogeneity in its clinical presentation and impact. PsA affects a wide range of musculoskeletal (MSK) tissues, including peripheral joints, enthesitis (insertion site of a tendon, ligament, or joint capsule onto bone), and is associated with dactyliitis (swelling of an entire digit). Comorbidities and extra-MSK manifestations also have important implications for management. Combinations of disease features may indicate a “phenotype” that could inform their disease course. To improve treatment strategies and long-term outcomes, there is a critical need to understand the association between subgroups of PsA with therapy response.

In this proposal, we aim to use a multicenter longitudinal cohort to (1) Identify PsA phenotypes and the probability of change in phenotype over time; and (2) Identify PsA patients with a high probability of responding to therapy and those with a low probability of responding to therapy. These aims are the first key steps towards personalized medicine in PsA through characterization of PsA phenotypes and using disease characteristics to predict therapy response.

Through the outlined career development plan and the proposed research, Dr. Karmacharya will gain the required skills to achieve independence and to address his long-term objectives. He will leverage the existing R01 funded study led by his mentor to address the research aims. With Vanderbilt’s commitment to young investigators, expertise in machine learning and personalized medicine, and outstanding mentorship, he will successfully leverage his innovative proposal for NIH K-award funding.
Mixed connective tissue disease (MCTD) features the formation of IgG autoantibodies (autoAb) specific for parts of the U1-snRNP spliceosomal complex. A strong link to the MHC II molecule, HLA-DRB1*0401 (DR4), and the presence of IgG autoAb, suggest the importance of CD4+ T cells in MCTD. Defining the specific, self-reactive CD4+ T cell populations that underlie this disease could help in developing specific therapies.

U1-snRNP is composed of U1-RNA bound by U1-70k, U1-A, and U1-C proteins. We used prediction algorithms to identify U1-70k peptides that strongly bind DR4, hypothesizing that these could serve as epitopes for self-reactive CD4+ T cells. These peptides were exchanged into DR4 tetramers and facilitated the detection of naive, self-reactive CD4+ T cells in DR4 transgenic (DR4-Tg) mice. U1-70k:DR4-specific CD4+ T cells expanded 5-10-fold and became activated in DR4-Tg mice immunized with U1-70k peptides. A mouse model of MCTD has been previously described in which ~60% of DR4-Tg mice immunized with U1-70k protein and U1-RNA develop anti-U1-70k IgG, and ~50% develop interstitial lung disease (ILD) that histologically resembles the ILD seen in some MCTD patients. These novel tetramers and the established DR4-Tg mouse model provide new opportunities to study the role of self-reactive CD4+ T cells in the pathogenesis of MCTD. In Aim 1 of this proposal, we will comprehensively evaluate U1-70k, U1-A, and U1-C to find additional DR4-binding self-peptides that serve as self-epitopes in the established MCTD mouse model. We will develop additional DR4 tetramer reagents to determine the precursor frequencies of the corresponding naïve CD4+ T cells recognizing these epitopes. We will also determine if ablating Aire or Bim results in increased precursor frequencies of these self-reactive CD4+ T cells and increases disease penetrance in the MCTD mouse model. In Aim 2, we will test the hypothesis that U1-snRNP peptide:DR4-specific CD4+ T cells may be biased towards T follicular helper and T helper-1 or -17 phenotypes in animals that succumb to disease in the MCTD mouse model.

Notably, because they have been engineered with DR4, the tetramers developed in this study will be directly usable in studies of human patients with MCTD.
Self-reactive T cells are thought to contribute to the development of many autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. Unfortunately, many current therapies impair both protective immune cells and disease-causing self-reactive T cells, leading to adverse side-effects such as infection. Selective manipulation of disease-causing self-reactive T cells could transform our treatment approach to autoimmune diseases. The NR4A family of nuclear receptors is a promising candidate drug target to address this unmet need because it is specifically expressed in and restrains self-reactive lymphocytes. Although NR4A family members are thought to function as ligand-independent, constitutively active transcription factors (TFs), small molecule agonist and antagonist ligands have been described, rendering them druggable. However, full therapeutic exploitation of the NR4A family is currently limited by major gaps in knowledge regarding its biology in thymocytes and mature CD4 T cells. Using innovative mouse models, this proposal seeks to fill these knowledge gaps about NR4A TFs. Study of the NR4A family in developing thymocytes and CD4 T cells has been hampered by significant functional redundancy among its members and its critical role in the generation of regulatory T cells (Treg). Namely, deletion of multiple—but not individual—NR4A TFs in the germline or CD4 T cell lineage leads to systemic autoimmunity due to a lack of Treg. Thus, it has been impossible to unmask redundant functions of NR4A TFs in central and peripheral T cell tolerance.

We developed a mixed radiation bone marrow chimera approach that restores Treg homeostasis in mice to overcome this obstacle. Our preliminary data support cell-intrinsic roles for the NR4A family in both clonal deletion of self-reactive thymocytes (central tolerance) and in CD4 T cell anergy (peripheral tolerance). In this proposal, we employ this chimera approach to extend these observations and explore the mechanism by which the NR4A family enforce both central and peripheral T cell tolerance.

Thus, this proposal lays the foundation to develop drugs that target and amplify the regulatory behavior of the NR4A family as future treatments for autoimmune diseases.
The Association of the Glucocorticoid Toxicity Index (GTI) with Measures of Quality of Life and Health Care Resource Utilization

Glucocorticoids are the cornerstone of therapy for many rheumatic diseases but are associated with numerous toxicities that are concerning to both patients and providers. Previously, there was no standardized way to quantify these toxicities. The Glucocorticoid Toxicity Index (GTI) is a recently-developed tool used to assess and quantify change in glucocorticoid toxicity in longitudinal studies. Quantifying glucocorticoid toxicities is critical for the evaluation of new rheumatic disease treatments that offer the potential for greater efficacy, as well as reduced glucocorticoid exposure. The GTI is increasingly being used as an outcome measure in clinical trials evaluating novel steroid-sparing agents. Health-related quality of life (QoL) and health care resource utilization are two key measures that contribute to our understanding of the comprehensive value of novel medications. The associations between GTI scores, QoL, and health care resource utilization will help to better understand the significance of differences in GTI scores across different patients and across different treatment groups in clinical trials.

This proposal will leverage data from the ADVOCATE trial of avacopan in ANCA-associated vasculitis as well as a novel, real-world prospective cohort of rheumatic disease patients receiving glucocorticoid treatment that will be developed and followed longitudinally. Using data from both cohorts, we will evaluate the relationships between GTI scores and health-related QoL. Additionally, in the real-world, prospective cohort, we will evaluate the relationship of GTI scores with health care resource utilization. Our data will be the first to lead to provide validation of the GTI in a real-world cohort of patients, thus allowing for essential close monitoring and quantification of glucocorticoid toxicity in real-world practice, and anticipated findings will inform how GTI scores should be interpreted in both prospective clinical trials and real-world practice.

Successful completion of this project will lead to further studies evaluating use of the GTI in a variety of settings to better understand the impact of different steroid-sparing treatment regimens.
Children with systemic lupus erythematosus (SLE) have a high prevalence of antiphospholipid antibodies (aPL), yet research on thrombotic risks associated with aPL positivity is limited in the pediatric population. Many children with SLE and positive aPL are managed with prophylactic aspirin without a clear understanding of how aPL impact hypercoagulability. Thrombin generation can be a useful tool to assess the influence of aPL and monitor the impact of antiplatelet therapy on the balance of coagulation.

In this proposal, we will use thrombin generation to provide new insights into aPL-induced hypercoagulability in children with SLE. Additionally, we will investigate how aspirin modulates this phenotype and impacts global coagulopathy in children with SLE and aPL positivity.

In the future, these tools may provide information for risk stratification for children with SLE at risk of thrombosis and inform daily practice when considering thromboprophylaxis. Further research studying pediatric aPL positivity and risk factors for the development of thrombosis are necessary to help guide clinicians in managing these challenging patients.
**Understanding the Role of HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis**

Fibroblast-like synoviocytes (FLS) that are expanded in the rheumatoid arthritis (RA) synovium and associated with active disease are defined by high expression of MHC class II (HLA-DR+). These FLS were recently shown via single-cell RNA-sequencing (scRNA-seq) studies of RA synovial tissue to express pro-inflammatory cytokines and chemokines, which suggest interactions with tissue-infiltrating leukocytes.

In this project, we will investigate the etiology and functions of key populations of these FLS. Based on their specific locations within the synovial tissue, we hypothesize that these HLA-DR+ FLS have two divergent functions: those in the synovial sublining layer express specific cytokines and chemokines due to their interactions with interferon gamma (IFNg) and tumor necrosis factor-alpha (TNF)-expressing T cells, and HLA-DR+ FLS in the synovial lining layer express tissue-damaging matrix metalloproteinases (MMPs) and exhibit increased invasiveness due to their interactions with proinflammatory macrophages expressing Interleukin 1-beta (IL-1b) and TNF. To investigate this hypothesis, we will use multiparameter immunofluorescence of human RA synovial tissue to elucidate spatial positioning of HLA-DR+ FLS responding to TNF, IFNg, or IL-1b within the synovium in relation to T cells and macrophages. Using an in vitro co-culture system combined with bulk RNA-seq analyses, we will determine if the presence of activated T cells +/- inflammatory macrophages imparts upon FLS distinct transcriptional features of sublining versus lining HLA-DR+ FLS subtypes. Finally, we will use a fibroblast invasion assay to determine if the observed differences in FLS transcriptional profiles between co-culture conditions correlate with functional differences.

By understanding the drivers of these disease-associated FLS subtypes and how they affect cellular functions, we will uncover key receptors and ligands, pinpoint active pathways, and inform fibroblast-directed therapeutics.
Antiphospholipid syndrome (APS) is an autoimmune disease propelled by circulating antiphospholipid antibodies that is best known for causing thrombosis and pregnancy loss. Approximately one-third of APS cases are diagnosed in the context of systemic lupus erythematosus (SLE). The immunopathogenesis of APS and SLE are complex, with derangements present in both lymphoid- and myeloid-lineage cells. The latter compartment has received increased scrutiny in recent years, an example of which is the recognition of neutrophil extracellular trap (NET) release (also called NETosis) as an important player in both conditions. NETs are prothrombotic webs of decondensed extracellular chromatin and granule-derived proteins that are released by neutrophils in response to infectious and sterile stimuli. NETs play an important role in corraling infectious organisms; however, when dysregulated or released in the wrong space, NETs may promote thrombosis, endothelial damage, type I IFN production, and autoantibody formation. Previous studies have demonstrated how metabolism can guide immune cell fates. For example, in macrophages, switching from glycolysis to oxidative phosphorylation promotes a shift from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype. While accumulating evidence suggests that metabolic plasticity also guides some essential neutrophil functions, very few studies have examined the metabolic determinants of NETosis.

The underlying hypothesis shepherding this proposal is that dysregulated neutrophil metabolism contributes to the pathophysiology of APS and SLE, a deeper understanding of which is likely to illuminate new and more precise targets for therapy. Aim 1 will characterize the metabolic determinants of NETosis, especially as they relate to APS and SLE. Aim 2 will define the metabolic profile of neutrophils in APS and SLE patients and track them with measures of disease activity. Aim 3 will determine the effects of metabolic modulation on in vivo disease models, with particular focus on thrombotic and inflammatory phenotypes.

The information gathered in this project will lay the groundwork from which a therapeutic paradigm centered around modulating neutrophil metabolic pathways can be developed.
Established with a generous commitment from Mrs. Tobé and Dr. Stephen Malawista, this endowment ensures that physician scientists can continue their academic careers in vital rheumatic disease research.

The Tobé and Stephen E. Malawista, MD Endowment in Academic Rheumatology provides a permanent source of support in basic science research career development for early career investigators.
Deciphering the Mast Cell-Fibroblast Axis in Osteoarthritis

Osteoarthritis (OA) affects over 300 million people worldwide and is a significant cause of disability and health-related costs. There are currently no disease modifying treatments for OA and treatments remain palliative. OA is the result of chronic, low-grade inflammation characterized by activation of the innate immune system. Mast cells are one of the only immune cell populations that are enriched in OA synovium and are associated with increased inflammation and damage. Functional studies show that mast cells promote inflammation and joint destruction in OA, yet it is unclear how mast cells modulate disease in OA. Preliminary data utilizing multiparameter imaging that enables visualization of 50+ cellular markers show that mast cells primarily co-localized with CD34+ and CD90+ fibroblasts in human OA synovium. Little is known regarding the roles of fibroblasts subsets in OA; however, it has been shown that CD90+ fibroblasts primarily drive inflammation whereas CD90- fibroblasts mediate joint damage in rheumatoid arthritis.

We hypothesize that mast cells induce pro-inflammatory CD90+ and CD34+ fibroblasts which drive inflammation and damage in OA. To address this, we will combine gene expression analysis with multiparameter imaging to reconcile the functional anatomic roles of mast cells and distinct fibroblast subsets in OA. Additionally, we will perform mechanistic in vivo studies to determine the direct effect of mast cells on fibroblast subsets.

Completion of these Aims will reveal how mast cells and fibroblasts contribute to joint destruction and may potentially identify novel disease modifying targets in osteoarthritis.
Building the rheumatology workforce in order to satisfy the growing demand for rheumatologists and rheumatology professionals requires robust education and training opportunities.

The Education and Training Awards help to cultivate future generations of rheumatology professionals and ensure people with rheumatic diseases have access to the care they need.
The Fellowship Training Award for Workforce Expansion supports the training of a rheumatology fellow at an institution wanting to create a new slot, or has previously been unable to fill ACGME-approved slots due to funding constraints. We provide this award to ensure an adequate supply of rheumatology providers in all areas of the country.

Children’s Hospital of Los Angeles
Hackensack University Medical Center
Stanford University
Vanderbilt University Medical Center

*Funding for these awards was provided in part by the Andrejeski Fund for Fellowship Training.*
These Fellowship Training Awards support the training of a rheumatology fellow to provide a more robust and highly trained workforce to care for people with rheumatic disease.

**Beth Israel Deaconess Medical Center**

**Children’s Hospital of Philadelphia**

**Cincinnati Children’s Hospital Medical Center**

**Duke University**

**Georgetown University**

**Indiana University**

**Johns Hopkins University**

**Massachusetts General Hospital**

**Montefiore Medical Center**

**New York University**

**Oregon Health & Science University**

**Tufts Medical Center**

**Stanford University**

**University of California, Los Angeles**

**University of California, San Diego**

**University of California, San Francisco**

**University of Chicago**

**University of Colorado, Denver**

**University of Michigan**

**University of Minnesota**

**University of Nebraska Medical Center**

**University of Pennsylvania**

*Funding for these awards was provided in part by Amgen, Inc. and the Zellis Family Foundation.*
PAULA DE MERIEUX FELLOWSHIP TRAINING AWARD

The Paula De Merieux Fellowship Training Award provides support for the training of a promising rheumatology fellow who is an under-represented minority or a woman.

University of Alabama at Birmingham
RISE PILOT PROJECT AWARD

The RISE Pilot Project Award provides resources to support the training and career development of early-career researchers and clinicians interested in pursuing research using real world electronic health data in the field of rheumatology. The purpose is to support trainees interested in pursuing rheumatology research utilizing the RISE research database and increase the supply of rheumatology professionals with knowledge of analytics using real-world data.

John Bridges, MD
University of Alabama at Birmingham
Contraception Prescribing Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry

Sebastian Sattui, MD
University of Pittsburgh
Characteristics of Patients and Treatments for Polymyalgia Rheumatica under Rheumatology Care: Analysis from the Rheumatology Informatics System for Effectiveness (RISE)

*Funding for these awards was provided in part by the American College of Rheumatology.
The Pediatric Visiting Professorship supports a board-certified professor of pediatric rheumatology to visit an academic institution that lacks expertise in the field to provide medical students and residents valuable exposure to pediatric rheumatology.

Jay Mehta, MD, MSEd to visit Virginia Tech Carilion School of Medicine

David Sherry, MD to visit Allegheny Health Network Medical Education Consortium

Randy Cron, MD, PhD to visit Louisiana State University

Sampath Prahalad, MD, MSc to visit Ochsner Clinic Foundation

Mary Moore, MD to visit Ascension St. John Hospital

Tracey Wright, MD to visit University of California (Irvine)

Susan Shenoi, MBBS, MS, RhMSUS to visit Cedars-Sinai Medical Center

Kelly Rouster-Stevens, MD, MS to visit Medical College of Georgia at Augusta University
PEDIATRIC VISITING PROFESSORSHIP

Robert Fuhlbrigge, MD, PhD to visit University of Tennessee

Jim Jarvis, MD to visit Temple University

B. Anne Eberhard, MD, MSc to visit Icahn School of Medicine at Mount Sinai

Megan Curran, MD to visit NYU Long Island School of Medicine

Jennifer Huggins, MD to visit Detroit Medical Center - Wayne State University

Brandi Stevens, MD, MSCR to visit Rush University Children’s Hospital

*Funding for these awards was provided in part by Amgen, Inc.*
MENTORED NURSE PRACTITIONER / PHYSICIAN ASSISTANT AWARDS FOR WORKFORCE EXPANSION

The Mentored Nurse Practitioner/Physician Assistant Award for Workforce Expansion provides tailored training for nurse practitioners or physician assistants who are new to the field of rheumatology and who are in geographically underserved areas.

**Idaho Arthritis & Osteoporosis Center PC**
Mikael Lagwinski, MD
Christopher Nicholas, MSN/FNP-C

**Idaho Arthritis & Osteoporosis Center PC**
Svetlana Meier, MD
Camille Buchmiller, PA-C

**Massachusetts General Hospital**
Sara R. Schoenfeld, MD
Elizabeth Patrick O’Connor, APRN

**Overlake Arthritis and Osteoporosis Center**
Arinola Dada, MD
Cayla Alexander, ARNP

**Regents of the University of Minnesota**
Erik Peterson, MD, BA
Megan Schoebel, PA and Corinna Werner, NP

**SSK Physician Associates, PA**
Swati Kumar, MD
Shalicia Riggins, MSN, FNP-C, FNP-BC

**SIMEDHealth, LLC**
Donald Scott, MD
Vera Brecken-Marquis, DNP, APRN, FNP-BC

**University of Kentucky Research Foundation**
Kristine Lohr, MD, MS, BA
January Hamby, APRN, AG-NP

**University of Texas MD Anderson Cancer Center**
Lu Huifang, MD, PhD
Linda Bobby, BSN, MSN
Preceptorships encourage students and residents to learn more about rheumatology and pursue careers in the field by supporting a one-on-one, real-world learning experience.
Rheumatology Future Physician Scientist Award

This award supports MD/PhD students who demonstrate outstanding potential and significant commitment to a career in rheumatology research, in order to support the nation’s top emerging physician scientists in the field of rheumatology.
The central objective of this project is to elucidate the combined contributions of citrullinated and malondialdehyde-acetaldehyde modified proteins in regulating cellular and immune responses in the context of rheumatoid arthritis (RA) pathogenesis.

We will examine the central objective through two Specific Aims that (1) Determine the role of citrullination and MAA-modification of proteins in activating different cell types (macrophages and fibroblasts); and (2) Evaluate immune responses in mice immunized with citrulline and/or MAA-modified proteins.

These studies will facilitate an understanding of how citrullination and MAA-modifications of different proteins contribute to immune responses that characterize RA and act as drivers of disease progression.
For many of the estimated 5 million people worldwide living with systemic lupus erythematosus (SLE), avoiding the sun is critical to management of their disease. SLE is a heterogeneous and debilitating autoimmune disorder which is characterized by overproduction of type I interferons (IFNs). Up to 70% of SLE patients experience skin manifestations, called cutaneous lupus erythematosus (CLE), that can be triggered by exposure to ultraviolet (UV) light. Although UV radiation is one of few well-described triggers in lupus, precise mechanisms and cell populations that drive UV-mediated inflammation are incompletely understood, identifying a critical need for better understanding of CLE to develop novel, targeted therapies.

In non-disease states, UV exposure leads to antigen-specific immunosuppression in the skin. However, in SLE skin, the immunosuppressive effects of UV light are lost likely secondary to chronic IFN production. Through single-cell analysis of cutaneous lupus lesions, our lab has identified an increase in an activated, IFN-educated, monocyte-derived CD16+ dendritic cell population in both lesional and non-lesional skin of lupus patients compared with healthy controls. The goal of this proposal is to define the mechanisms of recruitment of these cells and their ultimate contribution to lesional inflammation. To that end, we have turned to the lupus-prone NZM2328 (NZM), iNZM (lupus-prone mice lacking the type I IFN receptor) and wild-type Balb/c mouse models. In these models, we have preliminarily identified a type I IFN-dependent increase in monocyte recruitment, monocyte-derived DC (moDC) differentiation, and moDC activation in UV-exposed NZM skin compared with iNZM and wild-type. We will further determine the mechanism and consequence of monocyte recruitment following UV exposure, as well as the effect of type I IFN on moDC on antigen uptake, CD4+ T cell skewing, and cross-presentation following UV exposure. On completion of this project, we will have clarified UV- and IFN-induced mechanisms of moDC dysfunction in lupus skin and identified moDC dysfunction as an important IFN-dependent driver of photosensitive SLE skin disease, providing evidence for a novel target for future therapies.
Resident Research Preceptorship

The Resident Research Preceptorship introduces residents to the specialty of rheumatology and attracts promising physician scientists to the field by supporting a full-time research experience.

Philip Carlucci, MD
Jill Buyon, MD (Preceptor)
New York University School of Medicine

Krishnasai A. Madathanapalli, MBBS
Monique Hinchcliff, MD, MS (Preceptor)
Yale University School of Medicine

Daniele Marcy, MD
Kristen Demoruelle, MD, PhD (Preceptor)
University of Colorado School of Medicine

Bahtiyar Toz, MD
Betty Diamond, MD (Preceptor)
The Feinstein Institutes for Medical Research
Ephraim P. Engleman Endowed Resident Research Preceptorship

Jennifer Hanberg, MD
Zachary Wallace, Md, MSc (Preceptor)
Massachusetts General Hospital

Lawren H. Daltroy Health Professional Preceptorship

Megan Creasman, MD
Iris Navarro-Millán, MD, MSPH (Preceptor)
New York – Presbyterian / Weill Cornell Medical College
Medical and Graduate Student Preceptorship

The Medical and Graduate Student Preceptorship encourages medical and graduate students to consider a career in rheumatology by supporting a clinical or research mentorship with an established rheumatology professional.

Jeremy Adamson  
Shazia Beg, MD (Preceptor)  
University of Central Florida

Megan Armellini, DPT  
Daniel White, PT, ScD, MSc (Preceptor)  
University of Delaware

Priya Brito  
Sampath Prahalad, MD, MSc (Preceptor)  
Emory University

Jessica Browder***  
Diane L. Kamen, MD, MSCR (Preceptor)  
Medical University of South Carolina

Henry Chen  
Heidi Jacobe, MD, MSCS (Preceptor)  
University of Texas Southwestern

Kristina Deonaraine, MS*  
Jill Buyon, MD (Preceptor)  
The Research Foundation for the SUNY, University at Buffalo

Danielle Falkenstein***  
Jim Jarvis, MD (Preceptor)  
University of New York at Buffalo

Ashley Hodge  
Louise Thoma, PT, DPT, PhD (Preceptor)  
University of North Carolina at Chapel Hill

Brian Honick, DPT**  
Karin G. Silbernagel, PT, ATC, PhD (Preceptor)  
University of Delaware

Caitlyn Hott  
JoAnn Zell, MD (Preceptor)  
University of Colorado School of Medicine

Yuxuan Jiang  
Daniel Solomon, MD, MPH (Preceptor)  
Brigham and Woman’s Hospital

Katherine Ketcham  
Jennifer Stichman, MD (Preceptor)  
University of Colorado School of Medicine

Clinton Kimzey  
Melissa Griffith, MD (Preceptor)  
University of Colorado School of Medicine
Medical and Graduate Student Preceptorship

Raphael Kirou
Ellen Ginzler, MD, MPH (Preceptor)
State University of New York Downstate Medical Center

Catherine Lavallee
Melissa Lerman, MD, PhD (Preceptor)
The Children’s Hospital of Philadelphia

Soyoung Lee, MS
Deepak Kumar, PhD (Preceptor)
Boston University

Sydney Liles
Daniel K. White, PT, ScD, MSc (Preceptor)
University of Delaware

Miguel Locsin
Sampath Prahallad, MD (Preceptor)
Emory University/Children's Healthcare of Atlanta

Taylor Martinez, MS
M. Kristen Demoruelle, MD, PhD (Preceptor)
University of Colorado School of Medicine

Omkar Mayur***
Laura Carbone, MD (Preceptor)
Augusta University Research Institute

Erin McDonnell, MPH
Sharon Kolasinski, MD (Preceptor)
Trustees of the University of Pennsylvania

Lauren Mihalek
Louise Thoma, PT, DPT, PhD (Preceptor)
University of North Carolina at Chapel Hill

Mary Catherine Minnig, MS
Amanda Nelson, MD, MSCR, RhMSUS (Preceptor)
University of North Carolina at Chapel Hill

Megna Mishra
Louise Thoma, PT, DPT, PhD (Preceptor)
University of North Carolina at Chapel Hill

Sanjana Murthy
Shanthini Kasturi MD, MS (Preceptor)
Tufts Medical Center

Colleen Noonan
Daniel White, PT, ScD, MSc (Preceptor)
University of Delaware

Seong Hee (Joy) Park*
Andras Perl, MD (Preceptor)
SUNY Upstate Medical University

Niti Pawar
Patricia Katz, PhD (Preceptor)
University of California, San Francisco

Shivani Rangaswamy***
Julie Paik, MD (Preceptor)
Johns Hopkins University School of Medicine
Medical and Graduate Student Preceptorship

Rick Saha
Rachel Elizabeth Elam, MD (Preceptor)
Augusta University Research Institute

Donavon Sandoval-Heglund
Jinoos Yazdany, MD, MPH (Preceptor)
University of California, San Francisco

Ilan Schwell
Arundathi Jayatilleke, MD (Preceptor)
Temple University

Meena Afroze Shanta, MS
Salah-uddin Ahmed, PhD (Preceptor)
Washington State University, Spokane

Janya Sims
Wambui Machua, MD (Preceptor)
Piedmont Healthcare Foundation

Aliza Spielman**
Nancy Baker, ScD, MPH, OTR/L (Preceptor)
Tufts University

Shannon Teaw, MS
Monique Hinchcliff, MD, MS (Preceptor)
Yale University School of Medicine

James Sullivan
M. Elaine Husni, MD, MPH (Preceptor)
Cleveland Clinic Foundation

Amanda Walker*
Benjamin F. Chong, MD, MSCS (Preceptor)
University of Texas Southwestern Medical Center

Marshall Weber
Rachel Elizabeth Elam, MD, ScM (Preceptor)
Augusta University Research Institute

Joseph Whiting
Dan White, PT, ScD, MSc (Preceptor)
University of Delaware

Jeremy Wilson
Naureen Kabani, MD (Preceptor)
The Research Foundation for The State University

Kristin Wolf
Dan White, PT, ScD, MSc (Preceptor)
University of Delaware

*Funding for these awards was provided by the Marc R. Chevrier, MD, PhD, FACR, Lupus Research Memorial Fund.

**Funding for these awards was provided by the Daniel J. Wallace, MD Graduate Student Preceptorship Endowment.

***Funding for these awards was provided by the Majithia Family Endowment.
Cultivating an interest in rheumatology is essential to ensuring students, residents and fellows pursue careers in the field and help fill shortages, both academically and geographically. The ACR Convergence Awards recognize scholarship among aspiring rheumatology professionals.
Student & Resident ACR Convergence Scholarship

The Student and Resident ACR Convergence Scholarship encourages students and residents in areas of the U.S. underserved by rheumatology professionals to consider a career in the field by providing them the opportunity to experience rheumatology firsthand at ACR Convergence.

Anusheh Ali, MD
Louisiana State University Health Sciences

Emily Balczewski
University of Michigan Medical Center

Esther Bak, MD
University of Louisville

Michelle Vannessa Benjamin, MD
Louisiana State University, Shreveport

Diego Cabrera, MD
Yale-New Haven Hospital

Emilio Guzman Cisneros, MD
Duke University Medical Center

Jamie Morgan Visitacion Fernan, DO
Louisiana State University Health Sciences Center

Sayra Garcia, MS
Albert Einstein College of Medicine

Jenny Gong
Case Western Reserve University

Zhiyun Gong, MS
Dartmouth College

Maryam Hanoodi, MD
Vassar Brothers Medical Center

Fatima Hassan, MB, BCH, BAO
Louisiana State University Health Sciences

Malika Ibrahim, MBBS
Howard University

Naoaki Ito, DPT
University of Delaware

Helen Jarnagin
Dartmouth College

Sabah Khalafalla, MD, MB
Howard University

Victoria Gabriela Koenigsberger
Brown University

Jenna Lanz, MD
Columbia Presbyterian Medical Center
Christine Elizabeth Loftis, MD  
University of Texas Rio Grande Valley

Appledene Osbourne, MD  
University of California, Davis

Chanhyuk Park  
Dartmouth College

Eva Petrow, MD  
University of Rochester Medical Center

Roberta G. Marangoni, MD, PhD  
University of Rochester Medical Center

Madeline Morrisson  
Dartmouth College

Sherwin Novin, MD  
The University of North Carolina, Chapel Hill

Rezvan Parvizi  
Dartmouth College

Zachary T Peters  
Dartmouth College

Dillon Popovich  
Dartmouth College

Christeen Samuel  
Johns Hopkins University

Raisa Lomanto Silva, MD  
University of Pittsburgh

Alexandra Taylor  
Creighton University

Tiffany Taylor, MS  
University of California, San Francisco

Danya Waqfi, MD  
Vanderbuilt University Medical Center

Eyob Weyu, MS  
Regents of the University of Minnesota

Ezra Yu  
A.T. Still University of Health Sciences
Marshall J. Schiff, MD Memorial Fellow Research Award

The Marshall J. Schiff, MD, Memorial Fellow Research Award encourages fellows to continue rheumatology research and present an abstract at the ACR Convergence meeting.

**Caoilfhionn Marie Connolly, MD**  
Johns Hopkins University School of Medicine

**Rashmi Dhital, MD**  
University of California, San Diego

**Arash Mollaeian, MD**  
MetroHealth Medical Center, Cleveland, OH

**Jacquelyn Marie Nestor, MD, PhD**  
Massachusetts General Hospital

**Austin Michael Wheeler, MD**  
University of Nebraska Medical Center
Medical & Graduate Student Achievement Award

The Medical & Graduate Student Achievement Award encourages medical and graduate students to consider a career in rheumatology by recognizing promising work and providing an opportunity to present an abstract at ACR Convergence.

Nozima Aripova  
University of Nebraska Medical Center

Rebecca Brooks  
University of Nebraska Medical Center

Alessandra Ida Celia, MD  
Johns Hopkins University School of Medicine

Garrett Dunlap  
Brigham and Women’s Hospital

Mengdong He, MHS  
University of California, Los Angeles

Jason Thomas Jakiela, MS  
University of Delaware

Rhea Mehta, MHS  
University of Maryland

Zhe Miao, MS  
University of North Carolina at Chapel Hill

Maria Anna Schletzbaum, PhD  
University of Wisconsin

Suzanne Shoffner-Beck  
University of Michigan Medical Center
Medical & Pediatric Resident Research Award

The Medical and Pediatric Resident Research Award motivates residents to pursue subspecialty training in rheumatology by providing an opportunity to experience the field firsthand and present an abstract at ACR Convergence.

Shannon Herndon, MD
Duke University

Jonathan Katz, MD
University of Wisconsin Hospitals and Clinics

Marianne Kerski, MD
University of Michigan Medical Center

Alex Dragomir Luta, MD
MedStar Georgetown University Hospital

Avira Som, MD
Barnes-Jewish Hospital

Raeann Whitney, MD
Vanderbilt University Medical Center
The Pediatric Rheumatology Fellow Research Award motivates residents to pursue subspecialty training in pediatric rheumatology by providing an opportunity to experience the field firsthand and present an abstract at ACR Convergence.

**Kristina Alicia Ciaglia, MD**  
University of Texas Southwestern Medical Center

**Lauren Covert, MD**  
Duke University

**Erin Balay-Dustrude, MD**  
University of Washington

**Esraa Elloseily, MD**  
Children’s Hospital Medical Center

**Mariana Correia Marques, MD**  
National Institute of Arthritis, Musculoskeletal and Skin Diseases

**Anne Murphy, MD**  
University of Michigan

**Jessica Perfetto, MD**  
Children’s Hospital at Montefiore

**Megan Perron, MD**  
University of Colorado Denver

**Matthew Adam Sherman, MD**  
National Institute of Arthritis, Musculoskeletal and Skin Diseases

**Holly Michelle Wobma, MD, PhD**  
Boston Children’s Hospital
Memorial Lectureships

Memorial lectureships honor rheumatology professionals who have made significant contributions to the field during his or her lifetime. The lectureships are presented each year at the ACR Convergence and feature outstanding investigators in various areas of rheumatology research.

MEMORIAL LECTURESHIP TO HONOR
WILLIAM R. PALMER, MD, MACR
Michelle Ormseth, MD

EDMUND L. DUBOIS, MD MEMORIAL LECTURESHIP
Deepak A. Rao, MD, PhD

OSCAR S. GLUCK, MD MEMORIAL LECTURESHIP
Joel Block, MD

PHILIP S. HENCH, MD MEMORIAL LECTURESHIP
Fredrick Wigley, MD

PAUL KLEMPERER, MD MEMORIAL LECTURESHIP
Christopher Buckley, MD, PhD
The Rheumatology Research Foundation is able to fund cutting-edge research and the training of the next generation of rheumatology professionals because of the generous support of our donors, thank you.

If you would like to learn more about how you can make an impact at the Rheumatology Research Foundation, please contact Foundation@Rheumatology.org.